Rapid Dose Therapeutics Ships QuickStrip(TM) Production Line to Callan JMB's Texas cGMP Facility
Key Highlights
- ➤RDT shipped complete QuickStrip production line to Callan JMB’s Texas cGMP facility
- ➤Planned U.S. production remains subject to definitive agreements, qualification, and regulatory requirements
- ➤Shipment does not mark commencement of manufacturing operations at the Texas facility
- ➤Global oral thin films market projected to reach US$7.95 billion by 2034
Expert Statements
Mark Upsdell, CEO of Rapid Dose Therapeutics
“The shipment of our QuickStrip™ production line represents an important step in bringing our manufacturing technology closer to the U.S. market.”
Mark Upsdell, CEO of Rapid Dose Therapeutics
“By combining RDT's oral thin-film technology with Callan JMB's healthcare logistics capabilities, we see an opportunity to support future U.S.-based production.”
Mark Upsdell, CEO of Rapid Dose Therapeutics
“With evolving trade policies and tariffs adding complexity to cross-border operations, this initiative aligns with our broader strategy to strengthen our presence in the U.S. market.”
Mark Upsdell, CEO of Rapid Dose Therapeutics
“We look forward to working with Callan JMB as we advance this collaboration.”
Burlington, Ontario--(Newsfile Corp. - October 21, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company"), a Canadian biotechnology company specializing in oral thin-film drug delivery technology, today announced that it has shipped a complete QuickStrip™ production line to Callan JMB Inc. (NASDAQ: CJMB) ("Callan JMB") for planned installation at its cGMP facility in Texas, United States.
The shipment advances the collaboration outlined in Callan JMB's November 13, 2025, announcement, which described a preliminary agreement to install oral thin-film manufacturing equipment at its Texas facility while the companies negotiate operational arrangements.
Get started
Create a free account to read the full story.